United States

People: TBG Diagnostics Ltd (PGLA.PQ)

PGLA.PQ on OTC Markets Group

5 Aug 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Dredge, Keith 

Dr. Keith Dredge, Ph.D., is Director of Drug Development at Progen Pharmaceuticals Ltd. Mr. Dredge is a UK and European Registered Toxicologist with over 15 years of experience in drug development. He initially joined Progen in 2006 but returned in August 2013 as Director of Drug Development. In this role, he is responsible for the progression of drug candidates through Progen's pipeline. He has authored over 30 internationally-recognized scientific publications including several on Progen's proprietary technologies, particularly PG545 in Molecular Cancer Therapeutics, PLoS One, British Journal of Cancer and Investigational New Drugs. Previously, he held a management position at TetraQ, a GLP-recognised contract research organization at The University of Queensland (UQ) and academic positions at UQ and at St. George's University of London, UK where he published the first articles on Celgene's Revlimid and Pomalyst, now approved anti-cancer drugs. He obtained his Ph.D. in Pharmacology from the National University of Ireland, Galway and B.Sc. (Hons) in Toxicology from the Athlone Institute of Technology (Ireland). He is also a member of the American Association of Cancer Research (AACR).

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --